(ADMS) - Earnings & Price History

ADMS: - 26.21, $601.87M, 1.55 (6.29%)

Sector: Healthcare - Industry: Drugs - Generic

Adamas Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. The companys lead product candidate is the ADS-5102 that is in Phase 3 clinical development for the treatment of levodopa-induced dyskinesia, a movement disorder associated with Parkinsons disease; and in a Phase 2 clinical study for the treatment of symptoms associated with various sclerosis, including walking impairment. The companys portfolio also comprises of Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules. It has a licensing agreement with Forest Laboratories Holdings Limited for marketing Namzaric and Namenda XR. Adamas Pharmaceuticals, Inc. also engages in evaluating ADS-4101, an extended-release

Past ADMS reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2014-11-06Adamas Pharma-0.35-0.5715.0715.0815.0414.515.34-0.27%0.20%-0.07%62.80K
2014-08-12Adamas Pharma2.070.8816.7916.4916.616.2316.960.67%1.14%1.82%32.40K

Login | Register
Saturday May 26, 2018   EST
Enter a Ticker:

Economic Calendar

Durable Goods Orders 8:30 AM ET Consumer Sentiment 10:00 AM ET Charles Evans Speaks 11:45 AM ET Raphael Bostic Speaks 11:45 AM ET Robert Kaplan Speaks 11:45 AM ET Baker-Hughes Rig Count 1:00 PM ET SIFMA Rec. Early Close 2:00 ET  

AAII Sentiment Survey

BULL^ neut ^ BEAR


index chart
index color